Post-menopause:
what's still in play, what science truly says
You are on the other side. Periods disappeared over ten years ago, perhaps more. The body has found a new hormonal equilibrium, at stable low oestradiol levels, and most of the acute symptoms of the transition have faded.
This stability has a flip side. The metabolic, bone and cardiovascular transformations that began during the transition keep moving, more quietly. The curve is less noisy, but it continues.
This page will not make you regret what you didn't do before. It will state precisely what remains accessible.
The terrain
Early and late post-menopause: two different biologies.
Early vs late post-menopause
Post-menopause is defined as the period following twelve consecutive months of amenorrhoea. It splits into two phases: early post-menopause, up to six years after the final period, and late post-menopause, beyond that.
Bone and sarcopenia: two trajectories that feed each other
High-load strength training remains effective even late.
LIFTMOR: heavy strength training works
Two mutually reinforcing trajectories: bone loss, which slows after the sharp early-transition phase but remains continuous, and muscle loss (sarcopenia), which accelerates — on average 1 % per year after 60, and affects two women in three after 75.
A follow-up publication from the group in 2022 confirmed that women over 70 gain bone density and strength on the same protocol.
The therapeutic window: a gradient
Timing does not close abruptly — it fades.
A gradient, not a door
The therapeutic window mentioned for perimenopause is not a binary point but a gradient. For a woman in early post-menopause (first six years), the window remains largely open. Beyond ten to twelve years, evaluation becomes more cautious.
Insulin resistance and visceral adiposity
The quiet metabolic transition, probably the most decisive.
Silent visceral redistribution
Until the transition, oestradiol exerted a sensitising effect on insulin receptors and a distributing effect on adipose tissue. As it declines, both functions shift. Deep fat is not inert: it secretes inflammatory mediators and resists insulin action.
What a functional approach fully unfolds
Phytotherapy: what recent meta-analyses say.
Assessment: from fluctuating to terrain
In post-menopause, functional assessment shifts focus compared with perimenopause. Fluctuations are less the point; the settled terrain is.
Three foundational levers structure support: high-load strength training (LIFTMOR), distributed protein intake (PROT-AGE), and cofactor coverage (vitamin D, magnesium, B12, K2). These three levers are not alternatives: they are combined.
Intimacy: the most under-discussed territory
Genito-urinary syndrome: today treatable, without always going systemic.
The most under-discussed territory
Genito-urinary syndrome affects about 50 to 70 % of postmenopausal women and tends to worsen with the years, unlike vasomotor symptoms which fade. It includes vulvovaginal dryness, painful intercourse, recurrent urinary infections and urinary urgency.
Deepen a specific terrain
Access to all Nutrilexic articles for 7 days · £5. (validated by the most recent peer-reviewed scientific publications)
Why my heart switched sides after menopause
In ten years, will I still be solid?
Why I gain weight without eating more
What nobody really says about desire after menopause
Plants for menopause: a measured hormonal support
This exploration is educational. It does not replace individualised medical advice, particularly for decisions on hormone therapy and local preparations, which belong in a specialist consultation. Terms and conditions →
- El Khoudary SR et al.. « Menopause Transition and Cardiovascular Disease Risk (AHA Scientific Statement) ». Circulation, 2020.
- Watson SL et al.. « High-Intensity Resistance and Impact Training (LIFTMOR) ». J Bone Miner Res, 2018.
- Beckwée D et al.. « Exercise interventions for the prevention and treatment of sarcopenia: a systematic umbrella review ». J Am Med Dir Assoc, 2019.
- Bauer J et al.. « Evidence-based recommendations for optimal dietary protein intake (PROT-AGE) ». J Am Med Dir Assoc, 2013.
- Manson JE et al.. « Menopausal hormone therapy and long-term all-cause and cause-specific mortality ». JAMA, 2017.
- Gu Y et al.. « Timing and cardiovascular outcomes of menopausal hormone therapy ». Menopause, 2024.
- Contreras Garza et al.. « Endothelial estrogen receptor responsiveness and the timing hypothesis ». J Clin Endocrinol Metab, 2025.
- Lovejoy JC et al.. « Increased visceral fat and decreased energy expenditure during the menopausal transition ». Int J Obes (Lond), 2008.
- Nudy M et al.. « Menopausal transition and metabolic syndrome: a systematic review and meta-analysis ». J Endocr Soc, 2024.
- Anagnostis P et al.. « Menopause and diabetes: EMAS clinical guide ». Maturitas, 2020.
- Hosseinkhani A et al.. « Efficacy of S-equol in postmenopausal women: systematic review and meta-analysis ». Phytother Res, 2023.
- Castelo-Branco C et al.. « Updated review of Cimicifuga racemosa (iCR extract) in menopausal symptoms ». Climacteric, 2023.
- Danan ER et al.. « Effectiveness and safety of vaginal estrogens for genitourinary syndrome ». Annals of Internal Medicine, 2024.
- AHRQ. « Systematic Review: Genitourinary Syndrome of Menopause ». AHRQ Evidence Report, 2024.